ORIGINAL ARTICLE

A Prospective Case Control Study Comparing Serum Vitamin D Levels in Patients with and without Alopecia Areata

Wei Cheng Leong, MRCP, Madiha Muhamad Sarkan, AdvMDerm, Jyh Jong Tang, AdvMDerm

Dermatology Department, Hospital Raja Permaisuri Bainun Ipoh, Ministry of Health Malaysia

Abstract

Background

Alopecia areata (AA) is the most common cause of non-scarring alopecia.¹ Many studies reported decreased serum vitamin D levels in patients with AA compared to healthy subjects.¹⁻⁸ This study aimed to assess the prevalence of vitamin D deficiency in patients with AA compared to patients without AA. The secondary objective was to determine the correlation between vitamin D deficiency with disease severity and the pattern of AA.

Methods

This research was a case control study involving patients with AA from the dermatology clinic in Hospital Raja Permaisuri Bainun. All the subjects and controls were age, sex and Fitzpatrick skin type matched. Serum vitamin D (25-hydroxyvitamin D) (25 OHD) levels were obtained and analysed by the chemiluminescence immunoassay method. AA severity was assessed by Severity of Alopecia Tool (SALT) score.

Results

A total of 50 subjects, out of which 25 patients with AA and 25 controls, were recruited. The median serum vitamin D level was 54.15 nmol/L (IQR 139) in the AA group and 53.79 nmol/L (IQR 64.47) in the control group. However, the difference was not statistically significant (p=0.823). The prevalence of vitamin D deficiency was higher in the AA group (12%) compared to the control group (4%), but it was not statistically significant (p=0.304). There was no statistical significance in serum vitamin D levels with disease severity (SALT score) (p=0.171) and pattern of AA (p=0.657).

Conclusion

There was no statistical difference in the prevalence of vitamin D deficiency between patients with and without AA. There was no correlation between serum vitamin D levels with disease severity and pattern of AA. Further studies using a larger sample size is needed to justify measuring serum vitamin D levels in patients with AA.

Key words: Alopecia areata, Vitamin D, SALT score, Malaysia

Corresponding Author

Dr Leong Wei Cheng Department of Dermatology, Hospital Raja Permaisuri Bainun Ipoh, Jalan Raja Ashman Shah, 30450 Ipoh, Perak, Malaysia Email: leongweicheng@hotmail.com

Introduction

Alopecia areata (AA) is a common form of non-scarring hair loss.¹ AA usually presents as patches of hair loss on the scalp, but it may also involve any areas of hair-bearing skin.² AA is an organ-specific autoimmune disease exemplified by T-cell infiltrate and cytokine production around anagen-stage hair follicles.³ AA affects about 1-2% of the general

population, with an estimated lifetime risk of 1.7%.⁹ There is a higher prevalence in younger (21-40 years old) patients, but no significant difference in incidence exists between males and females.¹⁰ AA can profoundly affect a patient's quality of life, resembling the degree seen in other diseases, such as psoriasis and atopic dermatitis.¹¹ Vitamin D is a secosteroid hormone that is vital for calcium homeostasis and bone health.³ Vitamin D is also implicated in certain cancers, cardiovascular health and immune system.^{12,13,14}

Literature data suggest that vitamin D may be involved in the pathogenesis of AA due to its immunomodulatory effects.^{3,7} It has been shown that Vitamin D Receptors (VDRs) are strongly expressed in hair follicles. The lack of VDRs reduced epidermal differentiation and the growth of hair follicles.⁴ Some studies reported decreased serum vitamin D levels in AA in comparison to healthy subjects.¹⁻⁸ A significant negative correlation between Severity of Alopecia Tool Score (SALT score) and serum vitamin D was found in several studies.^{2,3,5,6,8} However, data concerning the correlation between vitamin D and clinical disease parameters were inconsistent.^{2,15} A study by Ghafoor R et al.16 showed that serum vitamin D levels were significantly lower in patients with AA than healthy controls. Yilmaz et al.¹⁷, however, did not find any correlation between serum vitamin D concentrations in 42 patients with AA and the extent of hair loss, number of patches, disease duration and nail involvement. Erpolat et al.¹⁸ conducted a case control study on 41 AA patients and found no statistically significant difference in the serum vitamin D levels between AA patients and healthy controls. Therefore, the vitamin D levels among patients in Malaysia with AA is not known.

The findings of our study may justify incorporating vitamin D supplements as adjunct therapy on top of the standard therapy. Our primary objective was to compare vitamin D deficiency in patients with or without AA. Secondary objectives were to assess the prevalence of vitamin D deficiency in patients with AA and determine the correlation of vitamin D deficiency with disease severity in patients with AA.

Materials and Methods Study design and subject recruitment

This was a prospective case control study conducted at the dermatology clinic of Hospital Raja Permaisuri Bainun Ipoh, Perak, Malaysia, between the period of May 2020 and November 2020. AA patients aged 12 years old and above were recruited into the study by a convenient sampling method. Exclusion criteria included pregnancy/lactating females; patients on oral vitamin D supplementation/topical vitamin D analogues, patients with other types of alopecia (such as tinea capitis, androgenic alopecia, trichotillomania, scarring alopecia, traction alopecia, telogen effluvium), patients with BMI>25(as vitamin D deficiency was associated with obesity)³ and patients with other systemic autoimmune diseases (e.g. vitiligo, rheumatoid arthritis, diabetes mellitus, thyroid disorder, lupus erythematosus etc.).

AA patients were interviewed to obtain demographic data, which consisted of their age, gender, ethnicity, Fitzpatrick skin phototype, education level, family history of AA, duration of the disease, presence of comorbidities, smoking and drinking habits, dietary restrictions and clothing practices.

Diagnosis of AA was based on clinical findings and dermatoscopy (to look for exclamation mark hairs, coudability, yellow dots, black dots, short vellus hair). Clinical data and clinical variables were documented. The duration of disease, site of involvement, severity assessment for scalp involvement (SALT score) and pattern of hair loss was recorded. Patients were asked to recall their 3-day diet history, which would subsequently be analysed for its vitamin D content using Nutritionist Pro[™] Software of the United States Department of Agriculture (USDA) Standard Reference Database, First DataBank, Inc., San Bruno, California.

The sun exposure index (SEI) was calculated

using the formula: hours of sun exposure per week multiplied by the fraction of BSA (body surface area involvement using the Wallace Rule of Nines chart) exposed to sunlight. Subjects in the control group were selected randomly among patients and hospital staff without alopecia. The controls were matched to age, sex and Fitzpatrick skin type. Similar exclusion criteria were applied to the control group. Control subjects were assessed clinically with detailed history and thorough examination. A total of 50 subjects were recruited with 25 AA patients and 25 healthy controls into each arm, respectively.

Serum vitamin D sampling and analysis

Three millilitres (ml) of venous blood was obtained from all subjects and transferred to a Lithium Heparin tube. Samples were collected and sent to the biochemical pathology laboratory in Hospital Raja Permaisuri Bainun Ipoh. The samples were centrifuged and transported to the biochemical pathology laboratory in Hospital Putrajaya. The blood samples were analysed by chemiluminescence immunoassay method through Beckham DXI analyser to measure serum total Vitamin D (25 -hydroxyvitamin D) (250HD) levels. Clinical decision values were defined as deficient (<25 nmol/L), insufficient (25-75 nmol/L), sufficient (76-250 nmol/L) and possible intoxication (>250 nmol/L).

Sample size calculations

The sample size of this study was calculated based on a systematic review and meta-analysis by Lee S *et al.*¹⁵ This sample size was calculated using Power and Sample Size Calculation version 3.1.2 with alpha = 0.05 and power = 80%. The sample size calculated was 46 (i.e. 23 subjects with AA and 23 subjects in the control group).

Data analysis

The Statistical Package for Social Sciences for Windows version 22.0 (SPSS, Chicago, IL, USA) was used to perform the statistical analysis. The data normality was checked by the Shapiro-Wilk test. The computed significance levels for age, BMI, vitamin D level, vitamin D category and vitamin D intake are > 0.05). Therefore, normality cannot be assumed, and a non-parametric test was performed. The descriptive data were expressed as median and inter quarter range, or frequency and percentage. Mann- Whitney test was used for the analysis of the difference between two study group means. Because of the small sample size of SALT 4 and SALT 5, and Ophiasis, Totalis and Universalis, they were collapsed into one single group, respectively (Naidu &Baddireddy 2020).¹⁹ Kruskal Wallis H test was used to determine the difference between the three study groups means; p < 0.05 was considered statistically significant.

Ethical approval

This study was registered with the National Medical Research Registry (NMRR-20-41-52526). Ethical approval for the study was obtained from the Medical Research and Ethics Committee, Ministry of Health, Malaysia.

Results

Table 1 shows the demographic and clinical characteristics of subjects with AA and controls. A total of 50 subjects were recruited, with 25 AA patients and 25 healthy controls in each arm, respectively. There was no significant difference (p>0.05) between the two groups regarding age, sex, BMI, race, education, comorbidities, smoking habits, alcohol intake, diet, Fitzpatrick skin type, medications, family history with AA and family history of autoimmune diseases.

The median vitamin D level was slightly higher in the AA group compared to the control group, although the difference was not statistically significant (54.15 nmol/L vs 53.79 nmol/L, p=0.823). The median vitamin D intake was higher in the control group (7.86 mcg; IQR 34.9) compared to the AA group (6.65 mcg; IQR:44), but the difference was not statistically significant (p=0.503). The median SEI was higher in the AA group (220.5; IQR: 209.8) compared to the control group (146.16; IQR: 863.7) even though the difference was not statistically significant (p=0.823). Vitamin D deficiency was higher in the AA group (12%) compared to the control

group (4%), while vitamin D insufficiency was found in 76% of AA patients and 92% in the control group. However, the results were not statistically significant (p=0.304). (Table 2)

Table 1. Demographic characteristics and clinical characteristics of subjects with and without alopecia areata (n = 50)

Median (IQR) or n (%) Age (in years) 29 (25) 29 (22) 0.938* Age (in years) 29 (25) 29 (22) 0.938* Sex 11 (44 %) 9 (36 %) 0.773* Female 14 (56 %) 16 (64 %) 0.839* BMI 23 (5.1) 22 (5.1) 0.839* Race 7 (28 %) 7 (28 %) 0.00% Chinese 9 (36 %) 9 (36 %) 0.00% Indian 9 (18 %) 9 (18 %) 0.00% Chinese 9 (36 %) 13 (52 %) 14 (56 %) 13 (52 %) Tertiary 9 (36 %) 12 (48 %) 0.00% 14 (50 %) 14 (50 %) 14 (50 %) 14 (50 %) 14 (50 %) 14 (50 %) 14 (50 %) 14 (50 %) 14 (50 %) 14 (50 %) 14 (50 %) 14 (50 %) 14 (50 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %) 12 (80 %	Demographic	Subject (AA) n = 25	Control n = 25	p value
Male 11 (44 %) 9 (36 %) 0.773 ^b Female 14 (56 %) 16 (64 %) 0.839 ^c BMI 23 (5.1) 22 (5.1) 0.839 ^c Race 7 (28 %) 7 (28 %) 0.00° Chinese 9 (36 %) 9 (36 %) 9 (36 %) 1.000° Chinese 9 (36 %) 9 (36 %) 9 (36 %) 1.000° Education 9 (36 %) 13 (52 %) 1.000° Primary 1 (4 %) 0 (0 %) 1.456° Secondary 15 (60 %) 13 (52 %) 1.000° Tertiary 9 (36 %) 12 (48 %) 0.289° No 18 (72 %) 22 (88 %) 1.000° No 20 (80 %) 20 (80 %) 20 (80 %) Ex-smoker 1 (4 %) 1 (4 %) 0.289° No 18 (72 %) 22 (88 %) <td></td> <td>29 (25)</td> <td>29 (22)</td> <td>0.938^c</td>		29 (25)	29 (22)	0.938 ^c
Female 14 (56 %) 16 (64 %) BMI 23 (5.1) 22 (5.1) 0.839° Race	Sex	-1		
BMI 23 (5.1) 22 (5.1) 0.839 ^c Race	Male	11 (44 %)	9 (36 %)	0.773 ^b
Race No 9 (36 %) 9 (36 %) 9 (36 %) 1.000° Chinese 9 (36 %) 9 (36 %) 9 (36 %) 1.000° Education 9 (18 %) 9 (18 %) 0 (0 %) 0.456° Secondary 15 (60 %) 13 (52 %) 0.456° Secondary 15 (60 %) 12 (48 %) 0.456° Tertiary 9 (36 %) 22 (88 %) 0.289% No 18 (72 %) 22 (88 %) 1.000° Smoker 1 (4 %) 1 (4 %) 1.000° No 20 (80 %) 20 (80 %) 1.000° Kachol 1 (4 %) 1 (4 %) 1.000° No 20 (80 %) 20 (80 %) 0.289% No 20 (80 %) 20 (80 %) 0.289% No 18 (72 %) 2 (8 %) 0.289% No 18 (72 %) 2 (8 %) 0.99% Non - vegetarian 2 (8 %) 0 (0 %) 1.000° Fitzpatrick 1 1.000° 1.000° Type III <	Female	14 (56 %)	16 (64 %)	1
Malay 7 (28 %) 7 (28 %) 9 (36 %) 1.00° Chinese 9 (36 %) 9 (36 %) 9 (36 %) 1.00° Education 9 (18 %) 9 (18 %) 9 (18 %) 0.0% Primary 1 (4 %) 0 (0 %) 0.456° Secondary 15 (60 %) 13 (52 %) 0.456° Tertiary 9 (36 %) 12 (48 %) 0.289° No 18 (72 %) 22 (88 %) 0.289° No 18 (72 %) 20 (80 %) 0.00° Ex-smoker 1 (4 %) 1 (4 %) 1.000° No 20 (80 %) 20 (80 %) 0.289° No 20 (80 %) 20 (80 %) 0.289° No 20 (80 %) 20 (80 %) 0.00° Yes 7 (28 %) 3 (12 %) 0.289° No 18 (72 %) 2 (8 %) 0.9° No 18 (72 %) 2 (100 %) 1.000° Type III 9 (36 %) 9 (36 %) 1.000° <td>BMI</td> <td>23 (5.1)</td> <td>22 (5.1)</td> <td>0.839°</td>	BMI	23 (5.1)	22 (5.1)	0.839°
Chinese 9 (36 %) 9 (36 %) Indian 9 (18 %) 9 (18 %) Education 9 (18 %) 9 (18 %) Primary 1 (4 %) 0 (0 %) 0.456° Secondary 15 (60 %) 13 (52 %) 0.456° Tertiary 9 (36 %) 12 (48 %) 0.289° Comorbid Yes 7 (28 %) 3 (12 %) 0.289° No 18 (72 %) 22 (88 %) 0.00° Ex-smoker 1 (4 %) 1 (4 %) 1.000° No 20 (80 %) 20 (80 %) 0.289° No 18 (72 %) 2 (8 8 %) 0.289° No 18 (72 %) 2 (8 8 %) 0.490° Non-vegetarian 2 (8 %) 0 (0 %) 1.000° Type IV 7 (28 %) 9 (36 %) $9 (36 \%)$ </td <td>Race</td> <td></td> <td></td> <td></td>	Race			
Indian 9 (18 %) 9 (18 %) Education $I (4 \%)$ 0 (0 %) 0.456° Secondary 15 (60 %) 13 (52 %) $I (4 \%)$ 0.0% Tertiary 9 (36 %) 12 (48 %) 0.289° Tertiary 9 (36 %) 3 (12 %) 0.289° No 18 (72 %) 22 (88 %) 0.289° Smoker 20 (80 %) 20 (80 %) 1.000° No 20 (80 %) 20 (80 %) 1.000° Kachol 1 (4 %) 1 (4 %) 1.000° Ves 7 (28 %) 3 (12 %) 0.289° No 20 (80 %) 20 (80 %) 0.00° Kachol 1 (4 %) 1 (4 %) 0.00° Yes 7 (28 %) 3 (12 %) 0.490° No 18 (72 %) 22 (88 %) 0.490° Non- vegetarian 23 (92 %) 25 (100 %) 1.000° Type III 9 (36 %) 9 (36 %) 1.000° Yes 8 (32 %) 12 (48 %)	Malay	7 (28 %)	7 (28 %)	1.000ª
Education F(1 + 9) $1 (4 %)$ $0 (0 %)$ 0.456° Secondary 15 (60 %) 13 (52 %) 0.456° Tertiary 9 (36 %) 12 (48 %) 0.289° Tertiary 9 (36 %) 3 (12 %) 0.289° No 18 (72 %) 22 (88 %) 0.289° Smoker 1 (4 %) 4 (16 %) 1.000° No 20 (80 %) 20 (80 %) 0.289° No 20 (80 %) 20 (80 %) 0.289° No 20 (80 %) 20 (80 %) 1.000° Resonker 1 (4 %) 1 (4 %) 0.289° No 20 (80 %) 20 (80 %) 0.289° No 20 (80 %) 20 (80 %) 0.289° No 18 (72 %) 22 (88 %) 0.289° No 18 (72 %) 25 (100 %) 0.490° Non - vegetarian 23 (92 %) 25 (100 %) 1.000° Type IV 7 (28 %) 7 (28 %) 1.000° <td< td=""><td>Chinese</td><td>9 (36 %)</td><td>9 (36 %)</td><td>1</td></td<>	Chinese	9 (36 %)	9 (36 %)	1
Primary 1 (4 %) 0 (0 %) 0.456° Secondary 15 (60 %) 13 (52 %) 0.456° Tertiary 9 (36 %) 12 (48 %) 0.289° Yes 7 (28 %) 3 (12 %) 0.289° No 18 (72 %) 22 (88 %) 0.289° Smoker 20 (80 %) 20 (80 %) 1.000° No 20 (80 %) 20 (80 %) 1.000° No 20 (80 %) 20 (80 %) 0.289° No 20 (80 %) 20 (80 %) 0.00° Kes 7 (28 %) 3 (12 %) 0.289° No 18 (72 %) 22 (88 %) 0.289° No 18 (72 %) 25 (100 %) 0.490° Non- vegetarian 23 (92 %) 25 (100 %) 0.490° Fitzpatrick 11 $9 (36 \%)$ $9 (36 \%)$ 1.000° Type III 9 (36 %) 9 (36 %) $9 (38 \%)$ 0.387° No 17 (68 %) 13 (52 %) 1.000° <	Indian	9 (18 %)	9 (18 %)	1
Secondary 15 (60 %) 13 (52 %) Tertiary 9 (36 %) 12 (48 %) Comorbid ($2 (48 %)$) ($2 (48 %)$) Yes 7 (28 %) 3 (12 %) $2.2 (88 %)$ No 18 (72 %) 22 (88 %) 1.000° Smoker 20 (80 %) 20 (80 %) 1.000° No 20 (80 %) 20 (80 %) 1.000° Ex-smoker 1 (4 %) 1 (4 %) 1.000° Alcohol 18 (72 %) 22 (88 %) 0.289° No 18 (72 %) 22 (88 %) 0.289° No 18 (72 %) 22 (88 %) 0.289° Non- vegetarian 23 (92 %) 25 (100 %) 0.490° Fitzpatrick Type III 9 (36 %) 9 (36 %) 1.000° Type IV 7 (28 %) 7 (28 %) 1.000° Type IV 7 (28 %) 9 (36 %) 0.387° No 17 (68 %) 13 (52 %) 0.387° No 17 (68 %) 13 (52 %)	Education			
Tertiary 9 (36 %) 12 (48 %) Comorbid 12 (48 %) Yes 7 (28 %) 3 (12 %) 0.289 ^k No 18 (72 %) 22 (88 %) 1.000 ^k Smoker 20 (80 %) 20 (80 %) 1.000 ^k No 20 (80 %) 20 (80 %) 1.000 ^k No 20 (80 %) 20 (80 %) 20 (80 %) Ex-smoker 1 (4 %) 1 (4 %) 1.000 ^k Alcohol 20 (80 %) 20 (80 %) 0.289 ^k No 20 (80 %) 20 (80 %) 0.289 ^k No 20 (80 %) 20 (80 %) 0.289 ^k No 18 (72 %) 22 (88 %) 0.289 ^k No 18 (72 %) 21 (88 %) 0.289 ^k Non- vegetarian 23 (92 %) 25 (100 %) 0.490 ^k Fitzpatrick 1.000 ^k 1.000 ^k 1.000 ^k Type IV 7 (28 %) 9 (36 %) 9 (36 %) 0.387 ^k No 17 (68 %) 13 (52 %) 1.000 ^k Famil	Primary	1 (4 %)	0 (0 %)	0.456ª
Comorbid $7 (28 \%)$ $3 (12 \%)$ 0.289^{\flat} No $18 (72 \%)$ $22 (88 \%)$ 0.289^{\flat} Smoker $22 (88 \%)$ 1.000° Yes $4 (16 \%)$ $4 (16 \%)$ 1.000° No $20 (80 \%)$ $20 (80 \%)$ 1.000° No $20 (80 \%)$ $20 (80 \%)$ 0.289° Ex-smoker $1 (4 \%)$ $1 (4 \%)$ 0.289° Alcohol $20 (80 \%)$ $21 (88 \%)$ 0.289° No $18 (72 \%)$ $22 (88 \%)$ 0.490° Non- vegetarian $23 (92 \%)$ $25 (100 \%)$ 0.490° Type III $9 (36 \%)$ $9 (36 \%)$ 1.000° Type V $9 (36 \%)$ $9 (36 \%)$ 0.387° No $17 (68 \%)$ $13 (52 \%)$ 1.000°	Secondary	15 (60 %)	13 (52 %)	1
Yes 7 (28 %) 3 (12 %) 0.289° No 18 (72 %) 22 (88 %) 0.289° Smoker 22 (88 %) 1.000° Yes 4 (16 %) 4 (16 %) 1.000° No 20 (80 %) 20 (80 %) 0.00° No 20 (80 %) 20 (80 %) 0.00° Ex-smoker 1 (4 %) 1 (4 %) 0.289° Alcohol 7 (28 %) 3 (12 %) 0.289° No 18 (72 %) 22 (88 %) 0.289° No 2 (8 %) 0 (0 %) 0.490° Non- vegetarian 23 (92 %) 25 (100 %) 0.490° Type IV 7 (28 %) 9 (36 %) 1.000° Type V 9 (36 %) 9 (36 %) 0.387° No 17 (68 %) 13 (52 %) 1	Tertiary	9 (36 %)	12 (48 %)	1
No 18 (72 %) 22 (88 %) Smoker 22 (88 %) Yes 4 (16 %) 4 (16 %) No 20 (80 %) 20 (80 %) Ex-smoker 1 (4 %) 1 (4 %) Alcohol 1 (4 %) 1 (4 %) Yes 7 (28 %) 3 (12 %) 0.289^{b} No 18 (72 %) 22 (88 %) 0.289^{b} Non-vegetarian 23 (92 %) 25 (100 %) 0.490^{b} Fitzpatrick Type IV 7 (28 %) 7 (28 %) 1.000^{a} Type V 9 (36 %) 9 (36 %) $9 (36 %)$ 0.387^{b} No 17 (68 %) 13 (52 %)	Comorbid			
SmokerYes4 (16 %)4 (16 %) 1.000^{μ} No20 (80 %)20 (80 %) 1.000^{μ} Ex-smoker1 (4 %)1 (4 %) 1.000^{μ} Alcohol1 (4 %)1 (4 %) 0.289^{μ} Yes7 (28 %)3 (12 %) 0.289^{μ} No18 (72 %)22 (88 %) 0.09^{μ} Diet2 (8 %)0 (0 %) 0.490^{μ} Non- vegetarian23 (92 %)25 (100 %)Fitzpatrick7 (28 %)9 (36 %) 1.000^{μ} Type III9 (36 %)9 (36 %) 1.000^{μ} Type V9 (36 %)13 (52 %) 1.000^{μ} No17 (68 %)13 (52 %) 1.000^{μ} No24 (96 %)25 (100 %) 1.000^{μ} Yes1 (4 %)0 (0 %) 1.000^{μ} No24 (96 %)25 (100 %) 1.000^{μ} Yes2 (8 %)2 (8 %) 1.000^{μ}	Yes	7 (28 %)	3 (12 %)	0.289 ^b
Yes4 (16 %)4 (16 %) 1.00^{μ} No20 (80 %)20 (80 %) 1.00^{μ} Ex-smoker1 (4 %)1 (4 %) 1.4% Alcohol7 (28 %)3 (12 %) 0.289^{μ} No18 (72 %)22 (88 %) 0.289^{μ} No18 (72 %)22 (88 %) 0.490^{μ} Diet $2(8 \%)$ $0 (0 \%)$ 0.490^{μ} Non-vegetarian23 (92 %)25 (100 %) 1.000^{μ} Fitzpatrick $7 (28 \%)$ $9 (36 \%)$ 1.000^{μ} Type III $9 (36 \%)$ $9 (36 \%)$ 0.387^{μ} No17 (68 %)13 (52 %) 1.000^{μ} Yes $8 (32 \%)$ 12 (48 %) 0.387^{μ} No17 (68 %)25 (100 %) 1.000^{μ} Family history AA $1 (4 \%)$ $0 (0 \%)$ 1.000^{μ} Yes $2 (8 \%)$ $2 (8 \%)$ $2 (8 \%)$ 1.000^{μ}	No	18 (72 %)	22 (88 %)	1
No 20 (80 %) 20 (80 %) Ex-smoker 1 (4 %) 1 (4 %) Alcohol 1 (4 %) 3 (12 %) 0.289^{b} No 18 (72 %) 22 (88 %) 0.289^{b} No 18 (72 %) 22 (88 %) 0.289^{b} Diet 22 (88 %) 0.490^{b} Non-vegetarian 23 (92 %) 25 (100 %) 0.490^{b} Fitzpatrick 1.000 ^a 1.000^{a} 1.000^{a} Type III 9 (36 %) 9 (36 %) $9 (36 %)$ 1.000^{a} Type V 9 (36 %) 9 (36 %) 1.000^{a} Type V 9 (36 %) 1.000^{a} 0.387^{b} No 17 (68 %) 13 (52 %) 0.387^{b} No 17 (68 %) 25 (100 %) 1.000^{b} Family history AA $24 (96 %)$ 25 (100 %) 1.000^{b} Family history Autoimmure $2 (8 \%)$ $2 (8 \%)$ 1.000^{b}	Smoker			
Ex-smoker 1 (4 %) 1 (4 %) Alcohol	Yes	4 (16 %)	4 (16 %)	1.000ª
Alcohol Image: Constraint of the sector of the	No	20 (80 %)	20 (80 %)	1
Yes7 (28 %)3 (12 %) 0.289^b No18 (72 %)22 (88 %) 0.289^b Diet22 (88 %) $0 (0 %)$ 0.490^b Non-vegetarian23 (92 %)25 (100 %) 0.490^b Fitzpatrick25 (100 %) 1.000^a Type III9 (36 %)9 (36 %) 1.000^a Type IV7 (28 %)7 (28 %) 0.387^b Type V9 (36 %)9 (36 %) 0.387^b Medications 0.387^b 0.387^b Yes8 (32 %)12 (48 %) 0.387^b No17 (68 %)13 (52 %) 1.000^b Family history AA $24 (96 %)$ 25 (100 %)Family history Autoimmure 1.000^b 1.000^b	Ex-smoker	1 (4 %)	1 (4 %)	1
No 18 (72 %) 22 (88 %) Diet	Alcohol			,
Diet 0 (0 %) 0.490% Vegetarian 2 (8 %) 0 (0 %) 0.490% Non- vegetarian 23 (92 %) 25 (100 %) 0.490% Fitzpatrick 23 (92 %) 25 (100 %) 1.000% Type III 9 (36 %) 9 (36 %) 1.000% Type IV 7 (28 %) 7 (28 %) 1.000% Type V 9 (36 %) 9 (36 %) 0.387% Medications 12 (48 %) 0.387% No 17 (68 %) 13 (52 %) 1.000% Family history AA Yes 1 (4 %) 0 (0 %) 1.000% No 24 (96 %) 25 (100 %) 1.000% Family history Autoimmure Yes 2 (8 %) 2 (8 %) 1.000%	Yes	7 (28 %)	3 (12 %)	0.289 ^b
Vegetarian 2 (8 %) 0 (0 %) 0.490 ^b Non-vegetarian 23 (92 %) 25 (100 %) 0.490 ^b Fitzpatrick 25 (100 %) 1.000 ^a 1.000 ^a Type III 9 (36 %) 9 (36 %) 1.000 ^a Type IV 7 (28 %) 7 (28 %) 1.000 ^a Type V 9 (36 %) 9 (36 %) 0.387 ^b Medications 12 (48 %) 0.387 ^b No 17 (68 %) 13 (52 %) 1.000 ^b Family history AA 24 (96 %) 25 (100 %) 1.000 ^b Family history Autoimmure 2 (8 %) 2 (8 %) 1.000 ^b	No	18 (72 %)	22 (88 %)	1
Non- vegetarian 23 (92 %) 25 (100 %) Fitzpatrick	Diet			
Fitzpatrick 9 (36 %) 9 (36 %) 1.000 ^a Type III 9 (36 %) 7 (28 %) 7 (28 %) 1.000 ^a Type IV 7 (28 %) 7 (28 %) 7 (28 %) 1.000 ^a Type V 9 (36 %) 9 (36 %) 9 (36 %) Medications Yes 8 (32 %) 12 (48 %) 0.387 ^b No 17 (68 %) 13 (52 %) Image: Constraint of the second	Vegetarian	2 (8 %)	0 (0 %)	0.490 ^b
Type III 9 (36 %) 9 (36 %) 1.000° Type IV 7 (28 %) 7 (28 %) 7 Type V 9 (36 %) 9 (36 %) 9 Type V 9 (36 %) 9 (36 %) 9 Medications 9 (36 %) 9 (36 %) 0.387 ^b No 17 (68 %) 13 (52 %) 0.387 ^b Family history AA I (4 %) 0 (0 %) 1.000 ^b No 24 (96 %) 25 (100 %) 1.000 ^b Family history Autoimmure I (2 (8 %)) 2 (8 %) 1.000 ^b	Non- vegetarian	23 (92 %)	25 (100 %)	
Type IV 7 (28 %) 7 (28 %) Type V 9 (36 %) 9 (36 %) Medications 9 (36 %) 9 (36 %) Yes 8 (32 %) 12 (48 %) 0.387 ^b No 17 (68 %) 13 (52 %) 0.387 ^b Family history AA Yes 1 (4 %) 0 (0 %) 1.000 ^b No 24 (96 %) 25 (100 %) 1.000 ^b Family history Autoimmune Yes 2 (8 %) 2 (8 %) 1.000 ^b	Fitzpatrick		1	1
Type V 9 (36 %) 9 (36 %) Medications 9 (36 %) 9 (36 %) Yes 8 (32 %) 12 (48 %) 0.387 ^b No 17 (68 %) 13 (52 %) 12 Family history AA 13 (52 %) 1.000 ^b No 24 (96 %) 25 (100 %) 1.000 ^b Family history Autoimmune Yes 2 (8 %) 2 (8 %) 1.000 ^b	Type III	9 (36 %)	9 (36 %)	1.000ª
Medications 8 (32 %) 12 (48 %) 0.387 ^b No 17 (68 %) 13 (52 %) 7 Family history AA 1 (4 %) 0 (0 %) 1.000 ^b No 24 (96 %) 25 (100 %) 1.000 ^b Family history Autoimmune 1.000 ^b 1.000 ^b	Type IV	7 (28 %)	7 (28 %)	1
Yes 8 (32 %) 12 (48 %) 0.387 ^b No 17 (68 %) 13 (52 %) 0 Family history AA Ves 1 (4 %) 0 (0 %) 1.000 ^b No 24 (96 %) 25 (100 %) 0 1.000 ^b Family history Autoimmune Ves 2 (8 %) 2 (8 %) 1.000 ^b	Type V	9 (36 %)	9 (36 %)	1
No 17 (68 %) 13 (52 %) Family history AA Yes 1 (4 %) 0 (0 %) 1.000 ^b No 24 (96 %) 25 (100 %) 1.000 ^b Family history Autoimmume Yes 2 (8 %) 1.000 ^b	Medications			
Family history AA Yes 1 (4 %) 0 (0 %) 1.000 ^b No 24 (96 %) 25 (100 %) Image: Colspan="2">Image: Colspan="2" Image: Colspan="2"	Yes	8 (32 %)	12 (48 %)	0.387 ^b
Yes 1 (4 %) 0 (0 %) 1.000 ^b No 24 (96 %) 25 (100 %) 1.000 ^b Family history Autoimmune Yes 2 (8 %) 2 (8 %) 1.000 ^b	No	17 (68 %)	13 (52 %)	
No 24 (96 %) 25 (100 %) Family history Autoimmune Image: Constraint of the second	Family history AA			
Family history Autoimmune Yes 2 (8 %) 2 (8 %) 1.000 ^b	Yes	1 (4 %)	0 (0 %)	1.000%
Yes 2 (8 %) 2 (8 %) 1.000 ^b	No	24 (96 %)	25 (100 %)	1
	Family history Autoimn	nune		
No 23 (92 %) 23 (92 %)	Yes	2 (8 %)	2 (8 %)	1.000 ^b
	No	23 (92 %)	23 (92 %)	1

^aChi-Square test; ^bFisher's exact test; ^cMann-Whitney test

0 1			
	Subject (AA) n =25 Median (IQR)	Control n =25 Median (IQR)	p value
Vitamin D level (nmol/L)	54.15 (139.0)	53.79 (64.47)	0.823a
Vitamin D intake (<i>mcgmcg</i>)	6.65 (44)	7.86 (34.9)	0.503ª
Sun Exposure index (SEI)	220.50 (209.8)	146.16 (863.7)	0.823ª
Vitamin D categories	n (%)	n (%)	
Deficient < 25	3 (12 %)	1 (4 %)	0.304 ^b
Insufficient 25-75	19 (76 %)	23 (92 %)	
Sufficient 76-250	3 (12 %)	1 (4 %)	

Table 2. Vitamin D level and deficiency in case and

^aMann-Whitney test; ^bChi-Square test

control group

The association of SALT score with vitamin D level was obtained by Kruskal-Wallis statistic and was interpreted as a chi-square value. There was no statistically significant association between SALT score and vitamin D levels (p=0.171). (Table 3)

Table 3. Association of SALT scores with vitamin D level

SALT subclass (n=25)	n (%)	Median (IQR)	<i>p</i> value
S1	18 (72 %)	54.56 (32.5)	0.171a
S2	2 (8 %)	34.42 (0)	
\$3-\$5	5 (20 %)	42.78 (43.13)	

^aKruskal-Wallis test

A similar analysis was performed for the association of AA patterns with vitamin D levels. The result showed no statistically significant difference between the pattern of AA with vitamin D levels (p=0.657). (Table 4)

Table 4. Association of pattern scores with vitamin D level

Pattern subclass (n=25)	n (%)	Median (IQR)	<i>p</i> value
P1 (patchy: single)	6 (24 %)	44.62 (37.29)	0.657ª
P2 (patchy: multiple)	15 (60 %)	54.16 (30.65)	
P3 (ophiasis, totalis and universalis)	4 (16 %)	43.49 (35.66)	

^aKruskal-Wallis test

Discussion

Vitamin D can be obtained from 3 sources: endogenous synthesis in the skin induced by ultraviolet B (UVB) radiation, dietary intake, and vitamin D supplementation.^{3,13,14} 7-dehydrocholesterol is the precursor molecule in the skin which absorbs UVB light and converts to vitamin D3(cholecalciferol). Vitamin D3 binds to vitamin D3 binding protein and is transported to the liver where it is hydroxylated to 25-hydroxyvitamin D (calcidiol) (25(OH)D). Calcidiol is then converted to 1,25-dihydroxyvitamin D3 (calcitriol) in the kidney by 1- α hydroxylase.^{13,14} The optimal level for 25-hydroxyvitamin D (250HD), the most stable and reliable parameter to evaluate vitamin D status, starts at 30 ng/ml, although the level of 250HD required to maintain optimum immune system homeostasis has yet to be established.²⁰

The active form of vitamin D (1,25-hydroxyvitamin D) acts by binding to specific vitamin D receptors found in the nucleus of target cells.⁷ Vitamin D Receptor (VDR) is highly expressed in the key structures of hair follicles, and it is vital for the maintenance of the normal hair cycle. It has been demonstrated that a lack of VDRs reduces the growth of hair follicles. Therefore, with the role of vitamin D and VDR in the hair cycle, it is hypothesised that vitamin D deficiency may have a role in AA.^{1,2}

A study conducted in Malaysia on vitamin D status in Malaysian men found that the prevalence of vitamin D deficiency was 0.5% and insufficiency was 22.7%, respectively.²¹ Numerous studies have shown that vitamin D insufficiency was common in tropical countries, including Vietnam, Malaysia, and Indonesia.²¹ The prevalence of vitamin D deficiency among Malaysian adolescents aged 13 years was 78.8%.²²

In our study, there was no significant difference in terms of the median vitamin D level between the AA and control group, even though the level was slightly higher in the AA group. A study by Nassiri *et al.*²⁴ found no statistically significant difference in serum vitamin D levels between AA cases and controls (ordinal odds ratio:0.49 (0.18-1.34 and 95%CI, p=0.16). Erpolat *et al.*¹⁸ also reported similar findings with mean serum

vitamin D levels of 8.1 ng/ml in AA patients compared to 9.8 ng/ml in healthy controls, which was not statistically significant (p > 0.05). In contrast, numerous studies reported high statistically significant lower vitamin D levels in cases compared to control. Aksu Cerman et al.³ reported significantly lower mean serum vitamin D levels in AA patients (11.84±6.18 ng/ml) than healthy controls (23.57±9.03 ng/ ml) (p < 0.001). A study conducted by Bhat *et* al.⁴ found a statistically significant difference in the mean serum vitamin D levels of AA patients (16.6±5.9 ng/ml) as compared to the control group (40.5 \pm 5.7 ng/ml) (p<0.001).⁴ Similar findings of high statistically significant lower vitamin D levels in AA cases compared to control was also reported in studies conducted by Sidappa et al.⁵, Mahamid et al.⁷, Rehman et al.8, and Yilmaz et al.17

Our study revealed that Vitamin D deficiency and insufficiency was high in both AA (12%, 76%) and control group (4%, 92%). This finding was consistent with recent studies, which showed vitamin D insufficiency was commonly found in tropical countries such as Vietnam, Malaysia and Indonesia.²¹ A study conducted by Kok-Yong Chin *et al.*²¹ found that the prevalence of vitamin D deficiency (<30 nmol/L) was 0.5% and insufficiency (30-50 nmol/L) was 22.7% among Malaysian men. The result of higher vitamin D deficiency and insufficiency in both groups in our study compared to Kok-Yong Chin et al.²¹ The discrepancy might be due to different definitions of vitamin D deficiency and insufficiency used in the study. Another study conducted in Malaysia by Moy *et al.*²³found that vitamin D insufficiency was observed in 67.9% of participants among Malay adults in Malaysia. Another study conducted by Rahman et al.²⁴ in Malaysia also showed a high prevalence of inadequate serum vitamin D levels among postmenopausal Malaysian women. A total of 73.3% of Malay postmenopausal women and 12.2% of Chinese postmenopausal women had insufficient serum vitamin D levels (<50 nmol/L).²⁴

In our study, there was no statistical difference in the prevalence of vitamin D deficiency between AA and the control group even though vitamin D deficiency was higher in the AA group than the control group (12% vs 4%, p>0.05). This observation could be due to a small sample size leading to insignificant results. Erpolat et al.18 also reported higher vitamin D deficiency in the AA group compared to control (93.8% vs 85.3%), but the difference was not statistically significant (p > 0.05). Numerous studies reported a significantly higher prevalence of vitamin D deficiency in AA compared to the control group. Suchana et al.1 reported 83.3% of vitamin D deficiency in the AA group compared to the control group (53.3%; p=0.01). Bakry et al.² found that 83.3% in the AA group versus 23.3% in the control group had deficient serum vitamin D levels (p < 0.001). Similar findings were reported by Aksu Cerman et al.3 and Naidu et $al.^{19}$

Our study did not find any statistically significant correlation between serum vitamin D levels and SALT scores. Suchana et al.¹ found that patients with more severe SALT scores tend to have lower serum vitamin D levels, with an inverse correlation (r=-.026, p=0.89); however, the results were not statistically significant. Naidu et al.¹⁹ also showed slightly lower serum vitamin D levels as the SALT score progressed, but the difference was not statistically significant (p=0.06). Various studies, as reported by Yilmaz et al.¹⁷, d'Ovidio et al.²⁰, El-Mongy et al.²⁵ and Darwish et al.²⁶ found no significant correlation between serum vitamin D levels with disease severity. However, this contradicts numerous other studies that found that serum vitamin D levels showed a significant negative correlation with disease severity.^{2,3,4,5,6,8} Aksu Cerman et al.³ found a significant inverse correlation between disease severity and serum vitamin D levels in AA patients (r =-0.730; p < 0.001). Bhat *et al.*⁴ also reported a significant negative correlation between SALT sore and vitamin D levels (r=-0.730; p < 0.001).⁴ Similar findings of significant inverse correlation between SALT score and vitamin D levels were reported by Sidappa et al.⁵, Gade et al.⁶, and Rehman et al.⁸

Regarding the correlation of serum vitamin D levels with the pattern of disease, our study

did not find any correlation between different patterns of AA with serum vitamin D levels. This finding was similar to a study conducted by El-Mongy et al.25, which reported no statistical significance between serum vitamin D levels and disease pattern (p=0.14). Similar findings were reported in studies conducted by Yilmaz et al.17,d'Ovidio et al.20 and Nassiri et al.27 In contrast, a study conducted by Bakry et $al.^2$ showed a gradual decline of serum vitamin D levels from patchy AA to Alopecia totalis/ universalis. Serum vitamin D levels of alopecia totalis/universalis patients were significantly lower when compared to patchy AA (p < 0.001) and ophiasis (p < 0.05). Rehman *et al.*⁸ also reported similar findings where serum vitamin D levels negatively correlated with the pattern of AA (r=-0.273, p=0.004).

The median SEI in the AA group was higher than the control group, although the result was not statistically significant (SEI: 220.50 vs 146.16, p > 0.05). A study conducted by Bingley et al.28 among 93 adults in Hawaii showed low serum vitamin D levels despite adequate sun exposure, suggesting variable responsiveness to UVB radiation among individuals.²⁸ A study conducted on 167 Malaysians by Wong et al.29 on sun exposure among healthy adults in a health facility showed a mean SEI of 160±144, lower than the median SEI of 220.5 in the AA group from our study.²⁹ Although Malaysia is a tropical country with adequate sunlight throughout the year, a low SEI among Malaysians can be attributed to sun avoidance to achieve a fairer skin tone, which is deemed more desirable, and escape the tropical heat. Other factors include the choice of clothing, with most Asians dresses modestly due to influence by tradition, culture, or religion, which limits the amount of sunlight that reaches the skin.29 The primary cause of vitamin D deficiency is inadequate exposure to sunlight.³⁰

The median vitamin D intake was lower in the AA group compared to the control group, although it was not statistically significant. Vitamin D intake was low in both groups, which correlates to low serum vitamin D levels in both groups. The finding could be attributed by very few foods that naturally contain or are adequately fortified with vitamin D. As examples, food sources that are naturally high in vitamin D include cod liver oil, salmon, sardines, tuna, shitake mushrooms and egg yolks. The recommended vitamin D intake is 600 IU/day (15 mcg) for adults aged 19-50 years old, and at least 600-800 IU/day (15-20 mcg) for adults aged 50-70 years old and above 70 years old, respectively. However, for serum vitamin D level to rise above 30 ng/ml (75 nmol/L), one may require 1500-2000 IU/day (38 mcg-50 mcg) of supplemental vitamin D.³⁰

Limitations

The limitations of this study include a relatively limited sample size. As this study was conducted from a single centre in Malaysia, larger studies involving multiple centres may be more representative of the population in Malaysia. In addition, as the patients were not followed up with vitamin D supplementation and repeated serum vitamin D levels, it was hard to conclude if vitamin D supplementation may be beneficial as an adjunctive treatment for patients with AA.

Conclusion

There is no significant statistical difference in vitamin D levels between patients with AA and without. However, the prevalence of vitamin D insufficiency was high in both AA and control groups. There is also no correlation between serum vitamin D levels with severity and pattern of disease.

Conflict of Interest Declaration

The authors have no conflict of interest to declare.

Acknowledgement

This study was funded with a research grant from the Dermatological Society of Malaysia. We would like to thank all the staff from the departments of dermatology and pathology of Hospital Raja Permaisuri Bainun, Ipoh and Hospital Putrajaya, and Suria Junus, the statistical supervisor. We also wish to thank the Director-General of Health Malaysia for permission to publish this article.

References

- Marahatta S, Agrawal S, Khan S. Study on Serum Vitamin D in Alopecia Areata Patients. J Nepal Health Res Counc 2019;17:21-5.
- 2. Bakry OA, El Farargy SM, El Shafiee MK, Soliman A. Serum Vitamin D in patients with alopecia areata. Indian Dermatol Online J 2016;7:371-7.
- Aksu Cerman A, Sarikaya Solak S, Kivanc Altunay I. Vitamin D deficiency in alopecia areata. Br J Dermatol 2014;170:1299-304.
- 4. Bhat YJ, Latif I, Malik R, Hassan I, Sheikh G, Lone KS et al. Vitamin D Level in Alopecia Areata. Indian J Dermatol 2017;62:407-10.
- Siddappa H, Kumar YHK, Vivekananda N. Evaluation of Association of Vitamin D in Alopecia Areata: A Casecontrol Study of 100 Patients in a Tertiary Rural Hospital of Southern India. Indian Dermatol Online J 2019;10:45-9.
- Gade VKV, Mony A, Munisamy M, Chandrashekar L, Rajappa M. An investigation of vitamin D status in alopecia areata. Clin Exp Med 2018;18:577-84.
- Mahamid M, Abu-Elhija O, Samamra M, Mahamid A, Nseir W. Association between vitamin D levels and alopecia areata. Isr Med Assoc J 2014;16:367-70.
- Rehman F, Dogra N, Wani MA. Serum Vitamin D Levels and Alopecia Areata- A Hospital Based Case-Control Study from North-India. Int J Trichology 2019;11:49-57.
- 9. Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers 2017;3:17011.
- Thompson JM, Mirza MA, Park MK, Qureshi AA, Cho E. The Role of Micronutrients in Alopecia Areata: A Review. Am J Clin Dermatol 2017;18:663-79.
- 11. Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. J Am Acad Dermatol 2016;75:806-12.
- Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev 2016;96:365-408.
- 13. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 2014;21:319-29.
- Kechichian E, Ezzedine K. Vitamin D and the Skin: An Update for Dermatologists. Am J Clin Dermatol 2018;19:223-35.
- 15. Lee S, Kim BJ, Lee CH, Lee WS. Increased prevalence of vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2018;32:1214-21.
- Ghafoor R, Anwar MI. Vitamin D Deficiency in Alopecia Areata. J Coll Physicians Surg Pak 2017;27:200-2.
- 17. Tsai TY, Huang YC. Vitamin D deficiency in patients with alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;78:207-9.
- Erpolat S, Sarifakioglu E, Ayyildiz A. 25-hydroxyvitamin D status in patients with alopecia areata. Postepy Dermatol Alergol 2017;34:248-52.
- Abedini R, Shakiba S, Ghandi N, Yazdaniamjad F, Haddadi N, Nasimi M. Study of vitamin D deficiency in patients with alopecia areata attending a dermatology center in Iran. Iran J Dermatol 2021;24:97-101.
- 20. d'Ovidio R, Vessio M, d'Ovidio FD. Reduced level of

25-hydroxyvitamin D in chronic/relapsing Alopecia Areata. Dermatoendocrinol 2013;5:271-3.

- Chin KY, Ima-Nirwana S, Ibrahim S, Mohamed IN, Wan Ngah WZ. Vitamin D status in Malaysian men and its associated factors. Nutrients 2014;6:5419-33.
- 22. Al-Sadat N, Majid HA, Sim PY, Su TT, Dahlui M, Abu Bakar MF et al. Vitamin D deficiency in Malaysian adolescents aged 13 years: findings from the Malaysian Health and Adolescents Longitudinal Research Team study (MyHeARTs). BMJ Open. 2016;6:e0106.
- Moy FM. Vitamin D status and its associated factors of free living Malay adults in a tropical country, Malaysia. J Photochem Photobiol B. 2011;104:444-8.
- 24. Rahman SA, Chee WS, Yassin Z, Chan SP. Vitamin D status among postmenopausal Malaysian women. Asia Pac J Clin Nutr 2004;13:255-60.
- El-Mongy NN, El-Nabarawy E, Hassaan SA, Younis ER, Shaker O.Serum 25-hydroxy vitamin D3 level in Egyptian patients with alopecia areata. J Egypt Women's Dermatologic Soc 2013;10:37-41.
- 26. Darwish NM, Marzok HF, Gaballah MA, Abdellatif HE. Serum level of vitamin D in patients with alopecia areata. Egypt J Basic Appl Sci 2017;4:9-14.
- 27. Soheila N, Zahra S, Shima Y. Association of Vitamin D level with alopecia areata. Iran J Dermatol 2013;16:1-5.
- 28. Binkley N, Novotny R, Krueger D, Kawahara T, Daida YG, Lensmeyer G et al. Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metab 2007;92:2130-5.
- 29. Wong LC, Jamil A, Md Nor N. Sun exposure among healthy adults in a health facility. Mal J Med HealthSci 2018;114:24-6.
- Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.